Keloid
Conditions
Interventions
Tofacitib group :Tofacitib 5mg qd
Baritinib group :Baritinib 2mg qd
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years and 1 year; 4. The number of skin lesions is >=5, and the area of a single keloid lesion is> 1cm^2 and the thickness is > 1mm; 5. No drugs and treatments that affected this treatment were used in the 3 months before the selection, including local hormone injections, oral tranilast, or shallow X-ray radiation therapy, etc.; 6. The patient has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who meet drug contraindications, allergic or intolerant to this product; 2. Patients suffering from severe viral, bacterial, fungal or parasitic infections; 3. Patients suffering from tumors, connective tissue diseases, blood system diseases, infectious diseases, organ transplants; 4. Pregnant or lactating women, those who are preparing to become pregnant; 5. Patients suffering from mental illness and involuntary ability; 6. With poor compliance and unable to follow up on time; 7. According to the researcher's judgment, the relevant medical history may interfere with the test results or increase the patient's risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vancouverscar scale;The Patient and Observer Scar Assessment Scale;ANTERA 3D; | — |
Secondary
| Measure | Time frame |
|---|---|
| Picture;Dermatology Life Quality Index; | — |
Countries
China
Contacts
Public ContactYang Bin
Dermatology Hospital of Southern Medical University
Outcome results
None listed